Should you buy Eli Lilly stock now?
The technical signal for Eli Lilly is currently Hold. Eli Lilly trades at $1,157.49 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -3.827 with falling momentum (signal: -3.720); RSI is at 48.5 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $1,328.83 points to 14.8% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Eli Lilly stock?
The average analyst price target for Eli Lilly is $1,328.83. The current price is $1,157.49, which gives an upside of 14.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $1,195.95 and $1,461.71.
Is Eli Lilly a dividend stock?
Yes, Eli Lilly is a dividend stock with a dividend yield of 0.57%. The latest dividend was $1.73 per share. The latest ex-dividend date (traded without the dividend) was Aug 14, 2026. The payout ratio is 21.2%, which is considered sustainable.
When does Eli Lilly pay a dividend in 2026?
The next dividend date for Eli Lilly has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Aug 14, 2026. The latest dividend was $1.73 per share with an ex-dividend date of Aug 14, 2026. The dividend yield is 0.57%. The payout ratio of 21.2% points to a sustainable dividend with room to grow.
What is the risk of Eli Lilly stock?
Eli Lilly is rated as a stock in the risk category Balanced. the annual standard deviation is 34.5%, which classifies the stock as Balanced.
Is Eli Lilly overvalued?
No, Eli Lilly is considered undervalued based on the analyst price target (14.8% upside). Eli Lilly has the following valuation ratios: a P/E ratio of 38.4 (highly valued), a P/S ratio of 12.8, a P/B ratio of 30.3. The analyst price target suggests that the stock is undervalued by 14.8%.
Is Eli Lilly overbought?
No, Eli Lilly is not overbought. RSI is at 48.5 (neutral zone). The technical indicators show: RSI is at 48.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.4% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Eli Lilly earnings report?
Eli Lilly reports its next earnings on October 29, 2026. The stock currently trades at $1,157.49. With a P/E ratio of 38.4, the market will be watching closely whether earnings meet expectations.
Is Eli Lilly shorted?
Eli Lilly has minimal short interest of 0.84% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Eli Lilly stock?
No, insiders are not buying Eli Lilly shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 15,958,170 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 471,179,902 $ sold. Active sellers include Jonsson Patrik, Zakrowski Donald A, Hakim Anat and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Eli Lilly a good stock?
Based on our total score, Eli Lilly is rated as a good stock with a total score of 60 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 15/100, Quality: 96/100, Momentum: 70/100. In addition: analysts see 14.8% upside to the price target; a dividend of 0.57%; technical signal: Hold. Whether Eli Lilly is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Eli Lilly stock?
The outlook for Eli Lilly based on current data: the average analyst price target is $1,328.83 (+14.8%); the next earnings report is due on Oct 29, 2026, which can move the price; the P/E ratio is 38.4 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Eli Lilly stock moving?
Eli Lilly is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Eli Lilly go?
The average analyst price target for Eli Lilly is $1,328.83, which corresponds to a potential gain of 14.8% from the current price of $1,157.49. The stock has traded between $778.94 and $1,292.65 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Eli Lilly fall?
The stock has traded as low as $778.94 over the last 52 weeks — that is 32.7% below the current price of $1,157.49. The biggest decline (drawdown) in the same period was 39.7% from high to low. Within a year, the price typically swings about ±34.5% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Eli Lilly do?
**What the company does**
Eli Lilly and Company develops, makes and sells medicines around the world. It earns money mainly by creating new treatments, especially for diabetes and cancer, and then selling them to hospitals, clinics and patients through healthcare systems.
**... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Eli Lilly as an investment.
Did Eli Lilly raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Eli Lilly. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Eli Lilly making money or losing money?
Yes, Eli Lilly is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 33.5% — which is excellent. The operating margin (profit before interest and taxes) is 54.2%. At a P/E ratio of 38.4, you currently pay 38.4 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Eli Lilly go bankrupt?
The bankruptcy risk of Eli Lilly is rated as low. Altman Z2 (a model for assessing financial distress) is 3.79 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 454% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Eli Lilly have a lot of debt?
Yes, Eli Lilly has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 454%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Eli Lilly service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 36.1x, and net debt equals 1.1 years of earnings (EBITDA).
